Showing 7 RESULTS FOR
Innovation
Across the Great Divide: Getting Antibodies into the Brain
A new collaboration studies an essential delivery avenue for innovative brain disease therapies.
Stronger Together: Why Collaboration is Critical to Advancing Alzheimer’s Research
By Peter Anastasiou
Lundbeck’s executive vice president and head of North America discusses our collaborative approach to Alzheimer’s research.
Lundbeck to Acquire Abide Therapeutics, Adding a Unique Discovery Platform and a Lead Compound in an Exploratory Phase IIa Program for Tourette’s
Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest, most diverse enzyme classes.
In the News: Chicago Sun-Times Covers Lundbeck’s Commitment to Alzheimer’s Research and New Alzheimer’s Treatments
Lundbeck's Doug Williamson, MD, is featured in a Chicago Sun-Times article about Alzheimer's disease research and new approaches to Alzheimer's treatments.
Report Offers Hope, Outlines 537 New Drugs in Development for Neurological Disorders
A new report shows there are 537 medicines in development for neurological disorders, such as Parkinson's disease and Alzheimer's disease. Learn how Lundbeck is advancing treatments for brain disorders.